Dosage · research context only
The CJC-1295 doses used in the research literature
What was administered, to which species, at which dose, by which route — reported as research values. This site does not provide human dosing for CJC-1295.
CJC-1295 Doses Used in the Research Literature
CJC-1295 dosage in the published literature is narrow and research-defined. Human pharmacokinetic studies used single subcutaneous doses of 30, 60, or 90 micrograms per kilogram [1] [3]. The GHRH-knockout mouse growth study used 2 micrograms per dose at intervals of 24, 48, or 72 hours [4]. These are the doses that generated the data this site summarizes — they are reported here as research values, not as a regimen for any person.
This site does not provide human dosing for CJC-1295. The compound is not approved for human use, and no validated human dose exists. Community and clinic "protocols" — commonly citing 100-to-300-microgram fixed doses for the no-DAC form or for CJC-1295 and ipamorelin combinations — are not derived from controlled human trials [1]. They circulate widely; they are not the published evidence.
How much CJC-1295 should I take?
This site does not provide human dosing. Published research used single subcutaneous doses of 30, 60, or 90 micrograms per kilogram in pharmacokinetic studies [1] [3], and GHRH-knockout mice received 2 micrograms per dose [4]. Community protocols are not derived from controlled human trials.
How much CJC-1295 DAC should I take?
No validated human dose exists. Human PK work with the long-acting DAC form used single subcutaneous doses of 30 to 90 micrograms per kilogram [1]; its 5.8-to-8.1-day half-life is why the DAC variant would be dosed far less frequently than the short-acting no-DAC form. Doses are reported here as research values only.
How much CJC-1295 / ipamorelin should I take?
No validated human combination dose exists, and this site does not provide one. The pairing rationale is mechanistic — a GHRH analog and a selective GHRP act through distinct receptors and synergize [1] — but circulating combination protocols are not derived from controlled human trials.
Routes and handling in the literature
Subcutaneous injection was the primary route in the human pharmacokinetic studies, with intravenous administration used in early GHRH(1-29) PK work [1]. Oral bioavailability is negligible — CJC-1295 is a peptide and would be degraded in the gut — so the studied routes are parenteral.
In research handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated. The four substitutions confer dipeptidylpeptidase-IV and protease resistance, and the DAC conjugation confers the multi-day duration; neither alters the fact that this is laboratory-handling context, not a human-use instruction [1].
How to reconstitute CJC-1295?
In research handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; oral bioavailability is negligible because it is a peptide [1]. This is laboratory-handling context, not a human-use instruction. CJC-1295 is not approved for human use.
Where to inject CJC-1295?
Research administration was subcutaneous, the primary route in the human pharmacokinetic studies [1]. This describes the route used in the literature, not a human-use recommendation; CJC-1295 is not approved for human use.
Why community protocols are not evidence
The gap between the published doses and the circulating "protocols" is the core of why a due-diligence reading matters. The published doses come from early-phase pharmacokinetic studies designed to characterize kinetics in small numbers of volunteers [1] [3]. The protocols come from forums and product pages, with no controlled-trial provenance and no efficacy or safety endpoints behind them.
This distinction is not pedantic. A dose with a half-life of 5.8 to 8.1 days behaves very differently from one cleared in hours, and a protocol that does not specify the variant — DAC or no-DAC — has not specified what it is dosing [1]. The DAC vs no-DAC pharmacokinetics page is the prerequisite for reading any dosing claim, and the full reference list is where the underlying studies can be checked directly.
The animal evidence reinforces why frequency, not just amount, is variant-dependent: in GHRH-knockout mice, two micrograms of CJC-1295 once every 24 hours normalized growth, while dosing every 48 to 72 hours was progressively less effective [4]. That schedule only makes sense for a long-acting compound. A dosing figure detached from its half-life and its species is a number without a context, which is exactly what most circulating protocols offer.